Anatomic Stage II Breast Cancer AJCC v8 trials recruiting in Connecticut

All Anatomic Stage II Breast Cancer AJCC v8 trials nationally

Cities in Connecticut

Recruiting trials in Connecticut

• Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
  NCT06058377 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: Derby, Fairfield, Glastonbury, Greenwich
• Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer
  NCT06582615 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years to 65 Years · Sex: Female · Connecticut: New Haven
• ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
  NCT06876714 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: Derby, Fairfield, Glastonbury, Greenwich
• Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
  NCT05929768 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: Avon, Bridgeport, Danbury, Derby
• Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
  NCT07391774 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: Stamford